Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™ in Nepalese
Learn more about:
Related Clinical Trial
First in Human Phase 1 Ascending Dose Study of PanChol in Healthy Volunteers
To Evaluate Safety of Oral Cholera Vaccine Hillchol® (BBV131)
A Phase III Randomized, Modified Double-blind, Multi-centric, Comparative Study, to Evaluate the Non-inferiority of Immunogenicity and Safety of Hillchol® (BBV131)to Shanchol™ Along With Lot-to-lot Consistency of Hillchol®(BBV131).
Immune Response to a Delayed Second Dose of Oral Cholera Vaccine
Preventative Intervention for Cholera for 7 Days
Impact Study of Cholera Vaccination in Endemic Areas – Clinical Surveillance
Water, Sanitation, and Hygiene Mobile Health Messages as an Innovative Tool to Facilitate Behavior Change
Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™ in Nepalese
Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants
Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults
Cholera-Hospital-Based-Intervention-for-7-days
PXVX0200 (CVD103-HgR) vs Shanchol in Mali
A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults
A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Adults
Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine (ShancholTM) in Nsanje Malawi
Single Dose Azithromycin in the Treatment of Adult Cholera
Safety and Immunogenicity of a New Formulation of Euvichol®
Cholera Anti-Secretory Treatment Trial
PK Study of iOWH032 in Adult Male/Female Healthy Volunteers & Adult Males With Cholera
Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial
Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults
Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine
Zinc Supplementation in Cholera Patients
Pilot Introduction of Oral Cholera Vaccine in Orissa, India
Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200
Immunity to Human Cholera in Bangladesh
Ciprofloxacin Multiple Dose for Adult Cholera
Immunologic Responses to a Live Attenuated Oral Cholera Vaccine
Effect of Probiotic on Immunogenicity of Oral Cholera Vaccine
Effectiveness of a Bivalent Killed Whole Cell Based Oral Cholera Vaccine
Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera
Impact Evaluation of Urban Water Supply Improvements on Cholera and Other Diarrhoeal Diseases in Uvira, Democratic Republic of Congo
Protective Immunity to Human Cholera in Bangladesh
Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine
Oral Cholera Vaccine Delivery in Rural Bangladesh
Study of Alternative Vaccination Schedule of Oral Cholera Vaccine
Mass Oral Cholera Vaccination in Zanzibar
Cholera Vaccine Investment Strategy in Bangladesh
Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine
Bridging Study for Killed Oral Cholera Vaccine in Ethiopia
Safety and Immunogenicity of Locally Manufactured Oral Cholera Vaccine
Single Dose Oral Cholera Vaccine Study in Dhaka, Bangladesh
Evaluation of a Boosting Regimen With Oral Cholera Vaccine
Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine
A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in Dominican Republic
Introduction of Cholera Vaccine in Bangladesh
Evaluation of a Pilot Program to Introduce Cholera Vaccine in Haiti as Part of Global Cholera Control Efforts
Single Dose Azithromycin to Prevent Cholera in Children
Safety and Immunogenicity of Oral Cholera Vaccine in Kolkata
A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines
Randomized Controlled Trial of Killed Oral Cholera Vaccine in Kolkata